- Home
- HURN vs RARE Comparison
HURN vs RARE Comparison
Compare HURN & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HURN
- RARE
- Stock Information
- Founded
- HURN 2002
- RARE 2010
- Country
- HURN United States
- RARE United States
- Employees
- HURN N/A
- RARE N/A
- Industry
- HURN Professional Services
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- HURN Consumer Discretionary
- RARE Health Care
- Exchange
- HURN Nasdaq
- RARE Nasdaq
- Market Cap
- HURN 2.6B
- RARE 2.6B
- IPO Year
- HURN 2004
- RARE 2014
- Fundamental
- Price
- HURN $149.94
- RARE $30.04
- Analyst Decision
- HURN Strong Buy
- RARE Strong Buy
- Analyst Count
- HURN 4
- RARE 14
- Target Price
- HURN $171.50
- RARE $86.64
- AVG Volume (30 Days)
- HURN 129.1K
- RARE 1.8M
- Earning Date
- HURN 10-28-2025
- RARE 11-04-2025
- Dividend Yield
- HURN N/A
- RARE N/A
- EPS Growth
- HURN 37.96
- RARE N/A
- EPS
- HURN 5.74
- RARE N/A
- Revenue
- HURN $1,556,665,000.00
- RARE $610,159,000.00
- Revenue This Year
- HURN $13.32
- RARE $19.72
- Revenue Next Year
- HURN $8.31
- RARE $23.29
- P/E Ratio
- HURN $26.20
- RARE N/A
- Revenue Growth
- HURN 9.24
- RARE 26.77
- 52 Week Low
- HURN $102.95
- RARE $25.81
- 52 Week High
- HURN $155.00
- RARE $58.00
- Technical
- Relative Strength Index (RSI)
- HURN 68.60
- RARE 51.17
- Support Level
- HURN $143.99
- RARE $29.60
- Resistance Level
- HURN $153.19
- RARE $31.70
- Average True Range (ATR)
- HURN 3.02
- RARE 1.22
- MACD
- HURN 0.41
- RARE 0.15
- Stochastic Oscillator
- HURN 73.73
- RARE 60.51
About HURN Huron Consulting Group Inc.
Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.